Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: GGTA1 KO Thymokidney Xenotransplantation in ESRD
NCT07224763Phase 2Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in end stage renal disease (ESRD), sponsored by United Therapeutics Corporation. Primary endpoints: Survival Rate of Patients with ESRD Receiving the GGTA1 KO Thymokidney at 24 weeks, Survival Rate of the GGTA1 KO Thymokidney at 24 weeks and 14 more. Started Nov 2026; status: recruiting.
02
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT07224763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224763.